LVA

Isabel Schnabel: From laggard to leader? Closing the euro area's technology gap

Retrieved on: 
Thursday, April 18, 2024
Orbis, NACE, PRT, Premium, Employment, FRA, Economics, ITA, BACH, LVA, European Commission, GTA, ECB, Risk, CEIC, Ageing, Intangibles, Policy, Person, NGEU, TFP, GDP, GRC, NLD, EIA, RHS, Bureau of Economic Analysis, Database, Digital, European Economic Association, Journal, LUX, AUT, JPN, Frontier, Harmful, Trade Data Monitor, Gérard Schivardi, Lost, Attention, Growth, LHS, LTU, RRF, COVID-19, Rubric, Productivity, Bank, Capital, HICP, Social, METI, Total
Key Points: 

Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries

Retrieved on: 
Tuesday, January 10, 2023
Philips, Patient, Health, Head, Surgeon, Lydus, LVA, FDA, Pharmaceutical industry, Teva

RA'ANANA, Israel, Jan. 10, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k).

Key Points: 
  • RA'ANANA, Israel, Jan. 10, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k).
  • An anastomosis is one of the most complicated steps of microvascular surgery and fundamental to the success of these demanding surgical interventions.
  • "FDA clearance of the Vesseal™ is a significant milestone both for innovation in microvascular anastomoses, and for Lydus Medical.
  • It is common knowledge that there are large clinical unmet needs around microvascular anastomosis," said Jessica Weiss, CEO Lydus Medical.

Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries

Retrieved on: 
Monday, January 9, 2023
Philips, Patient, Health, Head, Surgeon, Lydus, LVA, FDA, Pharmaceutical industry, Teva

RA'ANANA, Israel, Jan. 9, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k).

Key Points: 
  • RA'ANANA, Israel, Jan. 9, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k).
  • An anastomosis is one of the most complicated steps of microvascular surgery and fundamental to the success of these demanding surgical interventions.
  • "FDA clearance of the Vesseal™ is a significant milestone both for innovation in microvascular anastomoses, and for Lydus Medical.
  • It is common knowledge that there are large clinical unmet needs around microvascular anastomosis," said Jessica Weiss, CEO Lydus Medical.

United Launch Alliance Set to Launch the CST-100 Starliner Spacecraft on Orbital Flight Test-2

Retrieved on: 
Tuesday, May 17, 2022
Spaceflight Industries, Atlas, Orbit, 104th Fighter Wing, EDT, United Launch Alliance, Atlas V, ULA, Cape Canaveral Space Force Station, Health, AJ-60A, International Space Station, Centaur, Spacecraft, EDS, Boeing Orbital Flight Test 2, Industry, Weather, Emergency Detection System, LVA, Starliner, NMI, Commercial Crew Program, RD, Government, Space launch, NASA, Uncrewed spaceflights to the International Space Station, ISS, Boeing, Communications satellite

CAPE CANAVERAL SPACE FORCE STATION, Fla., May 17, 2022 /PRNewswire/ -- A United Launch Alliance (ULA) Atlas V rocket is in final preparations to launch Boeing's CST-100 Starliner spacecraft on the Orbital Flight Test-2 (OFT-2) to the International Space Station (ISS) for NASA's Commercial Crew Program.

Key Points: 
  • CAPE CANAVERAL SPACE FORCE STATION, Fla., May 17, 2022 /PRNewswire/ -- A United Launch Alliance (ULA) Atlas V rocket is in final preparations to launch Boeing's CST-100 Starliner spacecraft on the Orbital Flight Test-2 (OFT-2) to the International Space Station (ISS) for NASA's Commercial Crew Program.
  • The Atlas V rocket will deliver Boeing's Starliner spacecraft to a 98-nautical mile (nmi) sub-orbital trajectory.
  • This will be the 93rd launch of the Atlas V rocket and the 104th launch from Space Launch Complex-41.
  • For more information on ULA, visit the ULA website at www.ulalaunch.com , or call the ULA Launch Hotline at 1-877-ULA-4321 (852-4321).

Global Lymphedema Treatment Market Forecast (2021 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, February 28, 2022
Health, Oncology, Risk, National Center for Spinal Disorders, Neck, Partnership, Growth, Head, Time, Prevalence, Awareness, Secondary lymphedema, Primary lymphedema, NCBI, COVID-19, Industry, Breast cancer, Pharmacotherapy, National Center for Biotechnology Information, Disease, Edema, Hospital, Megasphaera, Swelling, Woman, Laser, Apollo Hospitals, National, Lymphedema, Breast, Lymphatic system, Cancer, Patient, Cleveland Clinic, National Cancer Institute, Ambulance, CAGR, Incidence, Cros, Pharmaceutical industry, Marketing, LVA

The "Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Condition Type, Treatment Type, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Condition Type, Treatment Type, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the lymphedema treatment market is attributed to the escalating incidence of secondary lymphedema, and the increasing number of healthcare services and lymphedema management programs.
  • Based on condition type, the global lymphedema treatment market has been segmented into primary lymphedema and secondary lymphedema.
  • Based on treatment type, the global lymphedema treatment market has been segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others.

Medical Microinstruments’ Symani® Surgical System Performs Lymph Node Transfer and Lymphovenous Anastomosis at the Renowned University Hospital Zurich

Retrieved on: 
Tuesday, August 10, 2021
Technology, Medical Devices, Sports, Hospitals, Other Technology, Surfing, Sailboarding, Biotechnology, Other Health, Health, Swelling, No, Birth, University Hospital of Zürich, MMI, Patient, Education, Research, Robotics, LVA, Blood, Thrombosis, Division, Surgeon, Hospital, Lymphedema, Bandini s.p. 1000, Microsurgery, ETH Zurich, Spondyloarthropathy, University Hospital (Newark, New Jersey), CE marking, University, USZ, Nursing, Plastic, ZEUS robotic surgical system, Dentistry

performed a lymph node transfer and lymphovenous anastomosis (LVA), a novel and challenging supermicrosurgical procedure intended to improve the patient's lymphedema by allowing outflow of lymphatic fluid through residual lymphatic channels.

Key Points: 
  • performed a lymph node transfer and lymphovenous anastomosis (LVA), a novel and challenging supermicrosurgical procedure intended to improve the patient's lymphedema by allowing outflow of lymphatic fluid through residual lymphatic channels.
  • 12 hospital in the world according to a recent poll in Newsweek , installed the Symani Surgical System in July to enhance its lymphatic surgery program.
  • The Symani Surgical System combines proprietary innovations including the worlds smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies.
  • The University Hospital Zurich (USZ) is internationally renowned for its achievements in university medicine, nursing, research and teaching.